<DOC>
	<DOCNO>NCT00003075</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use drug try prevent development cancer . Fenretinide may effective treat cervical neoplasia prevent cervical cancer . PURPOSE : Randomized double-blinded phase III trial compare effectiveness fenretinide placebo treat patient cervical neoplasia .</brief_summary>
	<brief_title>Fenretinide Treating Patients With Cervical Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy fenretinide ( N- ( 4-hydroxyphenyl ) retinamide ; 4-HPR ) regress cervical intraepithelial neoplasia ( CIN ) . II . Document qualitative quantitative toxicity 4-HPR woman CIN . OUTLINE : This double blind study . Patients randomize receive either fenretinide placebo . Patients administer fenretinide placebo mouth ( PO ) daily 6 month 3 day rest every month . Patients undergo colposcopy , colpophotography , Pap smear 3 , 6 , 9 , 12 month . Patients undergo cervical biopsy 6 12 month assess change . PROJECTED ACCRUAL : 84-100 patient accrue .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Fenretinide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose new recurrent cervical intraepithelial neoplasia grade 23 lesion involve least one quadrant transformation zone cervix PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 month Hematopoietic : Absolute granulocyte count great 1500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Other : Fertile patient must use effective contraception Fasting triglyceride less 2 time normal No prior malignancy Must consent colposcopy cervical biopsy PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>cervical intraepithelial neoplasia grade 2</keyword>
	<keyword>cervical intraepithelial neoplasia grade 3</keyword>
</DOC>